ul. Jaczewskiego 8
20-954 Lublin

tel.: 81 72 44 154
fax: 81 72 44 800


Badania naczyniowe i USG
tel.: 81 72 44 149
fax: 81 72 44 527

Badania rezonansu magnetycznego
tel.: 81 72 44 158
fax: 81 72 44 527


„Nie należy lekceważyć drobnostek, bo od nich zależy doskonałość.”

Michał Anioł (Michelangelo Buonarroti, 1475–1564)

Lublin - miasto inspiracji

ArtVentive announces positive clinical results and expanded enrolment in OCCLUDE I post-market surveillance study

ArtVentive has announced positive clinical results in conjunction with expanded enrolment in the ArtVentive Endoluminal Occlusion System (EOS device) OCCLUDE I post-market surveillance study.

ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced today excellent clinical results in conjunction with expanded enrollment in the ArtVentive Endoluminal Occlusion System, or ArtVentive EOS(TM) device, OCCLUDE I post-market surveillance study.

The Department of Interventional Radiology and Neuroradiology, Medical University of Lublin, Poland reported successful results for eleven cases over a two-day period. Professor Tomasz Jargiello served as the Primary Investigator and Professor Malgorzata Szczerbo-Trojanowska, head of the Department, Dr. Krzysztof Pyra and Dr. Michal Sojka each participated in the study. In conjunction with the study, four female patients were treated for pelvic congestion syndrome and seven male patients were treated for varicoceles using the ArtVentive EOS(TM) device.

"The ArtVentive EOS(TM) device performed extremely well and met all expectations in a clinical setting," Dr. Jargiello stated. "I was able to deliver the device with ease to the desired site and I was impressed with its simple deployment. The ArtVentive EOS(TM) device provided instant and complete occlusion of the target site. This is an improvement over other currently available occlusion devices and provided our team with confidence that the desired embolization was achieved."

"The OCCLUDE I venous and OCCLUDE II arterial post-market surveillance studies will compound our growing knowledge of the efficacy of the ArtVentive EOS(TM) device in vascular embolization treatments, expanding the already strong clinical application for the ArtVentive EOS(TM) system. Approximately eighty patients will be enrolled at up to ten study sites worldwide in the coming months," said Dr. Leon Rudakov, President and Chief Technology Officer.

Jim Graham, ArtVentive's Chief Executive Officer said, "It is gratifying that these cases have continued to validate our innovation and efforts over the past several years. The ArtVentive EOS(TM) platform offers significant clinical benefits and we look forward to gaining additional valuable insights from the OCCLUDE studies and expanding ArtVentive EOS(TM) platform's market potential."

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices featuring the ArtVentive EOS(TM).

The ArtVentive EOS(TM) is catheter-based, self-expandable and facilitates permanent or temporary occlusion of peripheral body lumens, cavities occurring within the body's vascular system and organ network. The ArtVentive EOS(TM) is designed to serve as a safe and reliable alternative to major surgery in certain cases. This technological innovation brings current interventional, image-guided techniques to a new level of sophistication, with the potential to resolve significant health issues.

The ArtVentive EOS(TM) serves as a proprietary technology platform for several major clinical areas, including peripheral and neurological vascular disorders, women's health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and interventional oncology procedures.

More information about ArtVentive can be found at

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company's current expectations, projections and beliefs concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company's control, and, thus, actual results could differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company's ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company's future results to differ materially from any forward-looking statements, see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.

Copyright © 2011 Zakład Radiologii Zabiegowej i Neuroradiologii SPSK4 Lublin
Projekt i wykonanie